A study in the Journal of Nuclear Medicine evaluated three F-18 labeled PET tracers with axitinib for assessment of antiangiogenic therapy response. Researchers conducted PET scans in mice with heterogeneous glioma and breast ductal carcinoma using PET tracers F-18 FDG, F-18 FLT and F-18 FtRGD, finding F-18 FLT allowed overall earlier detection of the therapeutic response, but each agent had different strengths. "These data suggest that differences in tumor biology may be critical for individual patient management and the choice of radiopharmaceutical agents for the noninvasive monitoring of therapy efficacy," the authors wrote.

Related Summaries